Time for a change: addressing R&D and commercialization challenges for antibacterials

ND4BB: addressing the antimicrobial resistance crisis

(2014) John H. Rex   NATURE REVIEWS MICROBIOLOGY

TRANSLOCATION Project: How to Get Good Drugs into Bad Bugs

(2014) R. A. Stavenger et al.   Science Translational Medicine

Siderophore conjugates

(2013) Malcolm G. P. Page   Annals of the New York Academy of Sciences

Improvement of the Pharmacokinetics andIn VivoAntibacterial Efficacy of a Novel Type IIa Topoisomerase Inhibitor by Formulation in Liposomes

(2013) Adam B. Shapiro et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Better Tests, Better Care: Improved Diagnostics for Infectious Diseases

(2013) A. M. Caliendo et al.   CLINICAL INFECTIOUS DISEASES

Host Response to Respiratory Bacterial Pathogens as Identified by Integrated Analysis of Human Gene Expression Data

(2013) Steven B. Smith et al.   PLoS One

Clostridium difficile infection in the twenty-first century

(2013) Chandrabali Ghose   Emerging Microbes & Infections

Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease

(2012) Patrick J. McEnaney et al.   ACS Chemical Biology

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Type IIA topoisomerase inhibition by a new class of antibacterial agents

(2010) Benjamin D. Bax et al.   NATURE

How to improve R&D productivity: the pharmaceutical industry's grand challenge

(2010) Steven M. Paul et al.   NATURE REVIEWS DRUG DISCOVERY